

Genetic basis of arrhythmogenic right ventricular dysplasia and brugada syndrome

K Jai Shankar

Department of Adult Cardiology, Institute of Cardio Vascular Diseases, The Madras Medical Mission, Chennai, India

Correspondence: K Jai Shankar, Department of Adult Cardiology, Institute of Cardio Vascular Diseases, The Madras Medical Mission, Chennai 600037, India, Email: drkjs68@yahoo.com

Received: November 10, 2017 | **Published:** November 14, 2017

Copyright© 2017 Shankar. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Sudden cardiac death is increasingly being recognized as a major contributor to mortality in young individuals. However, a significant number of them are unexplained. These are believed to be arrhythmogenic in origin. Sudden death may be the first manifestation of an inherited cardiac disorder. This is difficult to diagnose and genetic testing helps to improve its recognition. There has been considerable progress in the understanding about genetics of sudden cardiac death.

In arrhythmogenic right ventricular dysplasia (ARVD), five causative genes have been identified. However only 30% to 50% of the patients with ARVD are affected with one of these gene abnormalities. It is probable that other genes have not been identified. Frequently, patients have more than 1 genetic defect in the same gene or in a second complementary gene. A family member may have the gene

defect with development of disease or have no manifestations. Brugada syndrome is a hereditary disease responsible for ventricular fibrillation and sudden cardiac death in the young. This disease exhibits an autosomal dominant pattern of transmission with variable penetrance. The mean age of onset of events is around 40 years. Sudden death can affect individuals of any age; particularly men. 20–50% of cases have a family history of sudden death. Around 20–25% of cases have mutations in the SCN5A gene.

Clinical genetic testing is now commercially available. It is beneficial for first-degree family members to have genetic testing but only if there is a known genetic abnormality in the affected person. Time has now come for advising genetic counseling to the family members of the affected persons.